Dihexa Made in USA — Third-Party Verified
Dihexa is an oligopeptide variant derived from angiotensin IV that has drawn substantial attention in neurobiology and synaptic plasticity research. Synthesized domestically in the USA under strict quality protocols, PX1 Research provides batch-verified Dihexa exclusively for in vitro and laboratory research applications. Each lot undergoes rigorous HPLC/MS purity analysis and endotoxin testing to guarantee maximum experimental reproducibility.
Quick answer
Dihexa is an oligopeptide variant derived from angiotensin IV that has drawn substantial attention in neurobiology and synaptic plasticity research. Synthesized domestically in the USA under strict quality protocols, PX1 Research provides batch-verified Dihexa exclusively for in vitro and laboratory research applications. Each lot undergoes rigorous HPLC/MS purity analysis and endotoxin testing to guarantee maximum experimental reproducibility.
Key takeaways
- [Dihexa](/research-peptides/dihexa) (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an orally active, lipophilic oligopeptide fragment synthesized originally as an angiotensin IV analog.
- [Dihexa](/research-peptides/dihexa) features a short, hexapeptide-like structure with hydrophobic modifications that significantly alter its physicochemical properties relative to endogenous peptides.
- The primary mechanism of action characterized for [Dihexa](/research-peptides/dihexa) involves its high-affinity binding to hepatocyte growth factor (HGF).
- When evaluating peptidergic compounds that influence central nervous system pathways, investigators often contrast [Dihexa](/research-peptides/dihexa) with other synthetically modified or naturally occurring regulatory peptides.
Introduction to Dihexa in Neurobiological Research
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an orally active, lipophilic oligopeptide fragment synthesized originally as an angiotensin IV analog. In neurobiological research, angiotensin IV derivatives have been evaluated for their unique ability to interact with growth factor signaling cascades rather than traditional blood pressure regulation receptors.
Over the past decade, researchers investigating central nervous system (CNS) repair mechanisms have prioritized Dihexa due to its potent affinity for the hepatocyte growth factor (HGF) and its receptor tyrosine kinase, c-Met. Preclinical models suggest that Dihexa functions as an allosteric potentiator of HGF, facilitating dimerization and downstream intracellular signaling.
As interest in synaptic formation and dendritic arborization grows across preclinical paradigms, securing high-purity compounds becomes essential. PX1 Research supports domestic scientific endeavors by offering Dihexa made in USA, manufactured under stringent quality control systems to ensure uncompromised scientific integrity across the neurobiology research library.
Molecular Structure and Biochemical Characteristics
Dihexa features a short, hexapeptide-like structure with hydrophobic modifications that significantly alter its physicochemical properties relative to endogenous peptides. The addition of the N-hexanoic group enhances lipophilicity, enabling improved membrane permeability in cell culture assays and ex vivo tissue preparations.
Unlike unmodified linear peptides that suffer from rapid enzymatic degradation by aminopeptidases, Dihexa exhibits enhanced enzymatic stability in serum and tissue incubations. This stability makes it an excellent candidate for extended time-course in vitro experiments studying neuronal morphology, neurite outgrowth, and synaptic density.
When purchasing Dihexa research powder for quantitative assays, investigators must account for its solubility profile. Due to its hydrophobic N-terminal extension, Dihexa demonstrates optimal solubility in organic solvents such as dimethyl sulfoxide (DMSO) before secondary dilution into aqueous media or culture reagents.
Mechanistic Pathways: HGF/c-Met Signaling and Synaptogenesis
The primary mechanism of action characterized for Dihexa involves its high-affinity binding to hepatocyte growth factor (HGF). Preclinical studies indicate that Dihexa binds to HGF with picomolar affinity, stabilizing the active dimeric conformation required to phosphorylate the c-Met receptor.
Activation of the HGF/c-Met pathway initiates downstream signal transduction through the PI3K/Akt and MAPK/ERK pathways. In cultured hippocampal and cortical neuronal preparations, activation of these cascades has been observed to stimulate robust spinogenesis—the de novo creation of dendritic spines—and promote synaptic connectivity.
In vitro data indicate that Dihexa-induced c-Met activation occurs even in the presence of sub-threshold HGF concentrations. This synergistic mechanism allows researchers to examine spinogenetic rates and synaptic marker expression (such as PSD-95 and synaptophysin) across diverse animal cell lines and organotypic slice cultures.
Comparative Analysis: Dihexa vs. Other Neurogenic Research Peptides
When evaluating peptidergic compounds that influence central nervous system pathways, investigators often contrast Dihexa with other synthetically modified or naturally occurring regulatory peptides. While Dihexa targets the HGF/c-Met signaling axis directly, alternative compounds utilize neurotrophic, peptidergic, or enzymatic pathways.
For instance, the Semax research peptide operates primarily by modulating brain-derived neurotrophic factor (BDNF) expression and melanocortin receptor activity in rodent models. Similarly, Selank peptide exhibits anxiolytic-like properties in preclinical paradigms by altering GABAergic transmission and enkephalin stability rather than inducing structural spinogenesis via tyrosine kinase receptors. Meanwhile, copper-binding peptides like GHK-Cu peptide operate predominantly through tissue remodeling and gene transcription modulation.
Understanding these distinct mechanistic targets allows laboratory directors to select the appropriate biochemical probe for specific research hypotheses, whether focusing on direct dendritic spine induction (Dihexa), neurotrophin upregulation (Semax), or peptide hydrolysis stability (Selank).
The Importance of USA Synthesis and ISO 17025 Quality Control
The integrity of preclinical research depends entirely on the purity and consistency of the chemical reagents utilized. Offshore peptide synthesis often introduces batch-to-batch variability, residual heavy metals, TFA salts, or unreacted synthetic intermediates that corrupt cell viability assays and alter baseline signaling pathways.
PX1 Research mitigates these experimental variables by supplying exclusively domestic, USA-synthesized peptides. Synthesized in cGMP-compliant facilities, every batch of Dihexa made in USA undergoes multi-stage purification via preparative high-performance liquid chromatography (HPLC).
Following synthesis, independent testing is conducted through an accredited ISO 17025 laboratory. This rigorous analytical oversight guarantees that every vial shipped meets strictly enforced thresholds for identity, purity, and safety from microbial or chemical contaminants.
Analytical Verification: HPLC/MS, COA, and Endotoxin Testing
To ensure complete transparency, PX1 Research publishes lot-specific Certificate of Analysis (COA) documents for all inventory items. Investigators can verify product parameters prior to integration into sensitive laboratory workflows.
Purity is verified using reverse-phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum threshold of 98% purity. Mass Spectrometry (MS) is simultaneously performed to confirm the exact molecular weight (M+H+) and structural identity of the Dihexa molecule, ruling out deletion sequences or truncated peptide fragments.
Furthermore, because bacterial lipopolysaccharides (LPS) can trigger non-specific inflammatory responses in cell culture models, PX1 Research subjects every lot of Dihexa to chromogenic LAL endotoxin testing. This ensures endotoxin levels remain well below established threshold limits, preserving the validity of primary neuronal cell assays.
Laboratory Handling, Reconstitution, and Storage Protocols
Dihexa is supplied as a lyophilized, sterile powder to maintain long-term chemical stability. To prevent degradation, unopened vials should be stored at -20°C in a desiccated environment away from direct light exposure.
For laboratory reconstitution, researchers should handle the compound in a certified laminar flow hood using sterile, aseptic technique. Due to its lipophilic nature, initial dissolution in molecular-biology-grade DMSO at a concentrated stock solution (e.g., 10–50 mg/mL) is recommended prior to secondary dilution in phosphate-buffered saline (PBS) or cell culture media.
Repeated freeze-thaw cycles must be avoided as they accelerate peptide bond cleavage. Once reconstituted into working stock solutions, aliquots should be stored at -80°C and utilized within documented stability windows for in vitro assay protocols.
Institutional Supply and Bulk Procurement for Research Facilities
Academic institutions, biotechnology enterprises, and contract research organizations (CROs) require dependable supply chains capable of delivering large-scale peptide quantities with identical lot-to-lot purity specs.
PX1 Research supports institutional procurement through our institutional bulk supply program. By partnering directly with domestic synthesis laboratories, PX1 maintains stable inventory reserves, eliminating overseas customs delays and ensuring prompt dispatch for time-sensitive scientific research.
All institutional orders ship directly from our state-of-the-art facilities in California and Arizona, backed by dedicated technical support and full analytical documentation across our entire range of research peptides.
Frequently Asked Questions
Is Dihexa supplied by PX1 Research intended for human consumption?
No. Dihexa is supplied strictly as a research-grade chemical compound for in vitro, biochemical, and preclinical laboratory investigation. It is not for human or animal consumption, medical treatment, therapy, or clinical use.
Where is PX1 Research Dihexa synthesized?
PX1 Research Dihexa is 100% synthesized domestically in the United States within cGMP-compliant manufacturing facilities to ensure stringent purity and batch reproducibility.
How is the purity of Dihexa verified?
Every lot of Dihexa undergoes independent, third-party analytical testing at an ISO 17025 accredited laboratory. Purity is measured via RP-HPLC, identity is verified via Mass Spectrometry (MS), and endotoxin levels are measured using chromogenic LAL assays.
Where can I find the Certificate of Analysis (COA) for my lot?
Lot-specific COAs detailing HPLC purity graphs, mass spectrometry spectra, and endotoxin analysis are publicly accessible on the product page or provided directly with your order shipment.
What is the recommended reconstitution solvent for Dihexa in laboratory experiments?
Due to its hydrophobic nature, Dihexa dissolves most effectively in dimethyl sulfoxide (DMSO). Once fully dissolved in DMSO, it can be further diluted into aqueous buffer solutions such as PBS or culture media for in vitro assays.
How should lyophilized Dihexa be stored upon receipt?
Lyophilized Dihexa should be stored at -20°C in a dry, dark environment upon arrival. Reconstituted stock aliquots should be stored at -80°C to minimize degradation over time.
What is the primary biological pathway investigated with Dihexa?
In preclinical literature, Dihexa is primarily investigated for its high-affinity binding to Hepatocyte Growth Factor (HGF), which facilitates HGF/c-Met receptor dimerization and downstream spinogenesis signaling.
Does PX1 Research support bulk or institutional ordering?
Yes. PX1 Research offers flexible wholesale and institutional accounts for qualified academic and industrial research laboratories needing bulk quantities with guaranteed lot-to-lot consistency.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.